ROME IV FGIDs | Chapter 5: Pharmacological, Pharmacokinetic, and Pharmacogenomic Aspects of FGIDs

ROME IV FGIDs | Chapter 4: The Intestinal Microenvironment and Functional GIDs

ROME IV FGIDs | Chapter 6: Age, Gender, and Women’s Health and the Patient

Rouzade ML, Fioramonti J, Bueno L. A model for evaluation of gastric sensitivity in awake rats. Neurogastroenterol Motil 1998;10:157–163.
Mori T, Kawano K, Shishikura T. 5-HT3-receptor antagonist inhibits visceral pain differently in chemical and mechanical stimuli in rats. J Pharmacol Sci 2004;94:73–76.
Louvel D, Delvaux M, Staumont G, et al. Intracolonic injection of glycerol: a model for abdominal pain in irritable bowel syndrome? Gastroenterology 1996;110:351–361.
Bouin M, Delvaux M, Blanc C, et al. Intrarectal injection of glycerol induces hypersensitivity to rectal distension in healthy subjects without modifying rectal compliance. Eur J Gastroenterol Hepatol 2001;13:573–580.
Morteau O, Hachet T, Caussette M, et al. Experimental colitis alters visceromotor response to colorectal distension in awake rats. Dig Dis Sci 1994;39:1239–1248.
Al Chaer ED, Kawasaki M, Pasricha PJ. A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development. Gastroenterology 2000;119:1276–1285.
Gue M, Rio-Lacheze C, Eutamene H, et al. Stress-induced visceral hypersensitivity to rectal distension in rats: role of CRF and mast cells. Neurogastroenterol Motil 1997;9:271–279.
Coelho AM, Fioramonti J, Bueno L. Systemic lipopolysaccharide influences rectal sensitivity in rats: role of mast cells, cytokines, and vagus nerve. Am J Physiol 2000;279:G781–G790.
Barreau F, Cartier C, Ferrier L, et al. Nerve growth factor mediates alterations of colonic sensitivity and mucosal barrier induced by neonatal stress in rats. Gastroenterology 2004;127:524–534.
Woodsworth RS, Sherrington CS. A pseudo affective reflex and its spinal path. J Physiol 1904;31:234–243.
Kamp EH, Jones RC, III, Tillman SR, et al. Quantitative assessment and characterization of visceral nociception and hyperalgesia in mice. Am J Physiol 2003;284:G434–G444.
Ozaki N, Bielefeldt K, Sengupta JN, et al. Models of gastric hyperalgesia in the rat. Am J Physiol 2002;283:G666–G676.
Ness TJ, Gebhart GF. Colorectal distension as a noxious visceral stimulus: physiologic and pharmacologic characterization of pseudo affective reflexes in the rat. Brain Res 1988;450:153–169.
Su X, Julia V, Gebhart GF. Effects of intracolonic opioid receptor agonists on polymodal pelvic nerve afferent fibers in the rat. J Neurophysiol 2000;83:963–970.
Booth CE, Kirkup AJ, Hicks GA, et al. Somatostatin sst(2) receptor-mediated inhibition of mesenteric afferent nerves of the jejunum in the anesthetized rat. Gastroenterology 2001;121:358–369.
Fioramonti J, Gaultier E, Toulouse M, et al. Intestinal anti-nociceptive behaviour of NK3 receptor antagonism in conscious rats: evidence to support a peripheral mechanism of action. Neurogastroenterol Motil 2003;15:363–369.
Johnson AC, Myers B, Lazovic J, et al. Brain activation in response to visceral stimulation in rats with amygdala implants of corticosterone: an FMRI study. PLoS One 2010 Jan 5;5(1):e8573.
McLean PG, Picard C, Garcia-Villar R, et al. Effects of nematode infection on sensitivity to intestinal distension: role of tachykinin NK2 receptors. Eur J Pharmacol 1997;337:279–282.
Gue M, Junien JL, Bueno L. The kappa agonist fedotozine modulates colonic distention-induced inhibition of gastric motility and emptying in dogs. Gastroenterology 1994;107:1327–1334.
Tjeerdsma HC, Smout AJ, Akkermans LM. Voluntary suppression of defecation delays gastric emptying. Dig Dis Sci 1993;38:832–836.
Lee KJ, Tack J. Duodenal implications in the pathophysiology of functional dyspepsia. J Neurogastroenterol Motil 2010;16:251–257.
Gue M, Peeters T, Depoortere I, et al. Stress-induced changes in gastric emptying, postprandial motility, and plasma gut hormone levels in dogs. Gastroenterology 1989;97:1101–1107.
Al-Qarawi AA, Ali BH, Al-Mougy SA, et al. Gastrointestinal transit in mice treated with various extracts of date (Phoenix dactylifera L.). Food Chem Toxicol 2003;41:37–39.
Broccardo M, Improta G, Tabacco A. Central effect of SNC 80, a selective and systemically active delta-opioid receptor agonist, on gastrointestinal propulsion in the mouse. Eur J Pharmacol 1998;342:247–251.
Williams CL, Peterson JM, Villar RG, et al. Corticotropin-releasing factor directly mediates colonic responses to stress. Am J Physiol 1987;253:G582–G586.
Kadowaki M, Wade PR, Gershon MD. Participation of 5-HT3, 5-HT4, and nicotinic receptors in the peristaltic reflex of guinea pig distal colon. Am J Physiol 1996;271:G849–G857.
Cann PA, Read NW, Holdsworth CO. What is the benefit of coarse wheat bran in patients with irritable bowel syndrome? Gut 1984;25:168–173.
Cann PA, Read NW, Holdsworth CD, et al. Role of loperamide and placebo in management of irritable bowel syndrome. Dig Dis Sci 1984;29:239–247.
Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003;15:79–86.
Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001;15:1655–1666.
Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002;16:1877–1888.
Kellow J, Lee OY, Chang FY, et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003;52:671–676.
Emmanuel AV, Roy AJ, Nicholls TJ, et al. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther 2002;16:1347–1356.
Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001;120:354–360.
Andresen V, Camilleri M, Busciglio IA, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 2007;133:761–768.
Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012;107:1702–1712.
Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012;107:1714–1724.
von der Ohe MR, Camilleri M, Kvols LK, et al. Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. N Engl J Med 1993;329:1073–1078.
Plourde V, Lembo T, Shui Z, et al. Effects of the somatostatin analogue octreotide on rectal afferent nerves in human. Am J Physiol 1993;265:G742–G751.
Hasler WL, Soudah HC, Owyang C. A somatostatin analogue inhibits afferent pathways mediating perception of rectal distention. Gastroenterology 1993;104:1390–1397.
Hasler W, Soudah HC, Owyang C. Somatostatin analog inhibits afferent response to rectal distention in diarrhea-predominant irritable bowel patients. J Pharmacol Exp Ther 1994;268:1206–1211.
Bradette M, Delvaux M, Staumont G, et al. Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone. Dig Dis Sci 1994;39:1171–1178.
Lembo T, Naliboff BD, Matin K, et al. Irritable bowel syndrome patients show altered sensitivity to exogenous opioids. Pain 2000;87:137–147.
Coffin B, Farmachidi JP, Rueegg P, et al. Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther 2003;17:577–585.
Sturm A, Holtmann G, Goebell H, et al. Prokinetics in patients with gastroparesis: a systematic analysis. Digestion 1999;60:422–427.
Maganti K, Onyemere K, Jones MP. Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. Am J Gastroenterol 2003;98:259–263.
Janssen P, Harris MS, Jones M, et al. The relation between symptom improvement and gastric emptying in the treatment of diabetic and idiopathic gastroparesis. Am J Gastroenterol 2013;108:1382–1391.
Verhagen MA, Samsom M, Maes B, et al. Effects of a new motilide, ABT-229, on gastric emptying and postprandial antroduodenal motility in healthy volunteers. Aliment Pharmacol Ther 1997;11:1077–1086.
Talley NJ, Verlinden M, Snape W, et al. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2000;14:1653–1661.
Talley NJ, Verlinden M, Geenen DJ, et al. Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Gut 2001;49:395–401.
Cremonini F, Mullan BP, Camilleri M, et al. Performance characteristics of scintigraphic transit measurements for studies of experimental therapies. Aliment Pharmacol Ther 2002;16:1781–1790.
Tack J, Van Elzen B, Tytgat G, et al. A placebo-controlled trial of the 5-HT1A agonist R-137696 on symptoms, visceral hypersensitivity and on impaired accommodation in functional dyspepsia. Gastroenterology 2004;126(Suppl. 2):A70.
Read NW, Abitbol JL, Bardhan KD, et al. Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia. Gut 1997;41:664–668
Chial HJ, Camilleri C, Delgado-Aros S, et al. A nutrient drink test to assess maximum tolerated volume and postprandial symptoms: effects of gender, body mass index and age in health. Neurogastroenterol Motil 2002;14:249–253.
Arts J, Caenepeel P, Verbeke K, et al. Influence of erythromycin on gastric emptying and meal related symptoms in functional dyspepsia with delayed gastric emptying. Gut 2005;54:455–460.
Braak B, Klooker TK, Wouters MM, et al. Randomised clinical trial: the effects of amitriptyline on drinking capacity and symptoms in patients with functional dyspepsia, a double-blind placebo-controlled study. Aliment Pharmacol Ther 2011;34:638–648.
Janssen P, Verschueren S, Ly HG, et al. Intragastric pressure during food intake: a physiological and minimally invasive method to assess gastric accommodation. Neurogastroenterol Motil 2011;23:316–322, e153.
Simonian HP, Maurer AH, Knight LC, et al. Simultaneous assessment of gastric accommodation and emptying: studies with liquid and solid meals. J Nucl Med 2004;45:1155–1160.
Bouras EP, Delgado-Aros S, Camilleri M, et al. SPECT imaging of the stomach: comparison with barostat, and effects of sex, age, body mass index, and fundoplication. Single photon emission computed tomography. Gut 2002;51:781–786.
Briejer MR, Veen GJ, Akkermans LM, et al. Cisapride and structural analogs selectively enhance 5-hydroxytryptamine (5-HT)-induced purinergic neurotransmission in the guinea pig proximal colon. J Pharmacol Exp Ther 1995;274:641–648.
Briejer MR, Veen GJ, Akkermans LM, et al. Cisapride and structural analogs selectively enhance 5-hydroxytryptamine (5-HT)-induced purinergic neurotransmission in the guinea pig proximal colon. J Pharmacol Exp Ther 1995;274:641–648.
Morphy R, Kay C, Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov Today 2004;9:641–651.
Camilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000;355:1035–1040.
Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011;365:527–536.
Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome—results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009;29:329–341.
Sistonen J1, Fuselli S, Palo JU, et al. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genomics 2009;19:170–179.
Camilleri M, Bueno L, De Ponti F, et al. Pharmacological and pharmacokinetic aspects of functional gastrointestinal disorders. Gastroenterology 2006;130:1421–1434.
Shanahan F, Quigley EM. Manipulation of the microbiota for treatment of IBS and IBD—challenges and controversies. Gastroenterology 2014;146:1554–1563.
Mayer EA, Savidge T, Shulman RJ. Brain-gut microbiome interactions and functional bowel disorders. Gastroenterology 2014;146:1500–1512.
Raschi E, De Ponti F. Lubiprostone: pharmacokinetic, pharmacodynamic, safety and regulatory aspects in the treatment of constipation-predominant irritable bowel syndrome. Expert Opin Drug Metab Toxicol 2014;10:293–305.
Musch MW, Wang Y, Claud EC, et al. Lubiprostone decreases mouse colonic inner mucus layer thickness and alters intestinal microbiota. Dig Dis Sci 2013;58:668–677.
Keely S, Kelly CJ, Weissmueller T, et al. Activated fluid transport regulates bacterial-epithelial interactions and significantly shifts the murine colonic microbiome. Gut Microbes 2012;3:250–260.
Hao H, Zheng X, Wang G. Insights into drug discovery from natural medicines using reverse pharmacokinetics. Trends Pharmacol Sci 2014;35:168–177.
Cremonini F. Standardized herbal treatments on functional bowel disorders: moving from putative mechanisms of action to controlled clinical trials. Neurogastroenterol Motil 2014;26:893–900.
Chow EC, Pang KS. Why we need proper PBPK models to examine intestine and liver oral drug absorption. Curr Drug Metab 2013;14:57–79.
Zhang X, Wu W. Ligand-mediated active targeting for enhanced oral absorption. Drug Discov Today 2014;19:898–904.
De Ponti F, Poluzzi E, Montanaro N. Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus. Eur J Clin Pharmacol 2001;57:185–209.
Moynihan R. Alosetron: a case study in regulatory capture, or a victory for patients’ rights? BMJ 2002;325:592–595.
De Ponti F, Poluzzi E, Cavalli A, et al. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf 2002;25:263–286.
Gonsalkorale WM, Perrey C, Pravica V, et al. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 2003;52:91–93.
Camilleri M. Is there a SERT-ain association with IBS? Gut 2004;53:1396–1399.
Holtmann G, Siffert W, Haag S, et al. G-protein beta 3 subunit 825 CC genotype is associated with unexplained (functional) dyspepsia. Gastroenterology 2004;126:971–979.
Dalen P, Dahl ML, Ruiz ML, et al. 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 1998;63:444–452.
Glatt CE, Reus VI. Pharmacogenetics of monoamine transporters. Pharmacogenomics 2003;4:583–596.
Camilleri M, Atanasova E, Carlson PJ, et al. Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2002;123:425–432.
Li Y, Nie Y, Xie J, et al. The association of serotonin transporter genetic polymorphisms and irritable bowel syndrome and its influence on tegaserod treatment in Chinese patients. Dig Dig Sci 2007;52:2942–2949.
Lembo A, Camilleri M. Chronic constipation. N Engl J Med 2003;349:1360–1368.
O’Mahony L, McCarthy J, Kelly P, et al. A randomized, placebo-controlled, double-blind comparison of the probiotic bacteria lactobacillus and bifidobacterium in irritable bowel syndrome (IBS): symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541–551.
Lesbros-Pantoflickova D, Michetti P, Fried M, et al. Meta-analysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004;20:1253–1269.
Gershon MD, Jonakait GM. Uptake and release of 5-hydroxytryptamine by enteric 5-hydroxytryptaminergic neurones: effects of fluoxetine (Lilly 110140) and chlorimipramine. Br J Pharmacol 1979;66:7–9.
Gorard DA, Libby GW, Farthing MJ. 5-Hydroxytryptamine and human small intestinal motility: effect of inhibiting 5-hydroxytryptamine reuptake. Gut 1994;35:496–500.
De Ponti F. Pharmacology of serotonin: what a clinician should know. Gut 2004;53:1520–1535.
Bouras EP, Camilleri M, Burton DD, et al. Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans. Gut 1999;44:682–686.
Poen AC, Felt-Bersma RJ, Van Dongen PA, et al. Effect of prucalopride, a new enterokinetic agent, on gastrointestinal transit and anorectal function in healthy volunteers. Aliment Pharmacol Ther 1999;13:1493–1497.
Degen L, Matzinger D, Merz M, et al. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001;15:1745–1751.
Lim HC, Kim JH, Youn YH, et al. Effects of the addition of mosapride to gastroesophageal reflux disease patients on proton pump inhibitor: a prospective randomized, double-blind study. J Neurogastroenterol Motil 2013;19:495–502.
Fukazawa K, Furuta K, Adachi K, et al. Effects of mosapride on esophageal motor activity and esophagogastric junction compliance in healthy volunteers. J Gastroenterol 2014;49:1307–1313.
Cho YK, Choi MG, Park EY, et al. Effect of mosapride combined with esomeprazole improves esophageal peristaltic function in patients with gastroesophageal reflux disease: a study using high resolution manometry. Dig Dis Sci 2013;58:1035–1041.
Hongo M, Harasawa S, Mine T, et al. Large-scale randomized clinical study on functional dyspepsia treatment with mosapride or teprenone: Japan Mosapride Mega-Study (JMMS). J Gastroenterol Hepatol 2012;27:62–68.
Tack J, Vos R, Janssens J, et al. Influence of tegaserod on proximal gastric tone and on the perception of gastric distension. Aliment Pharmacol Ther 2003;18:1031–1037.
Tonini M, Cipollina L, Poluzzi E, et al. Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics. Aliment Pharmacol Ther 2004;19:379–390.
Moayyedi P, Soo S, Deeks J, et al. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2004;CD001960.
Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, et al. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol 2001;96:689–696.
Parkman HP, Carlson MR, Gonyer D. Metoclopramide nasal spray is effective in symptoms of gastroparesis in diabetics compared to conventional oral tablet. Neurogastroenterol Motil 2014;26:521–528.
Rossi M, Giorgi G. Domperidone and long QT syndrome. Curr Drug Saf 2010;5:257–262.
European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) recommends restricting use of domperidone. (http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Domperidone_31/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment_Committee/WC500162559.pdf, accessed February 23, 2015).
Huang X, Lv B, Zhang S, et al. Itopride therapy for functional dyspepsia: a meta-analysis. World J Gastroenterol 2012;18:7371–7377.
Talley NJ, Tack J, Ptak T, et al. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut 2008;57:740–746.
Holtmann G, Talley NJ, Liebregts T, et al. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med 2006;354:832–840.
Itoh Z. Motilin and clinical application. Peptides 1997;18:593–608.
Cuomo R, Vandaele P, Coulie B, et al. Influence of motilin on gastric fundus tone and on meal-induced satiety in man: role of cholinergic pathways. Am J Gastroenterol 2006;101:804–811
Bruley des Varannes S, Parys V, Ropert A, et al. Erythromycin enhances fasting and postprandial proximal gastric tone in humans. Gastroenterology 1995;109:32–39.
Piessevaux H, Tack J, Wilmer A, et al. Perception of changes in wall tension of the proximal stomach in humans. Gut 2001;49:203–208.
Annese V, Janssens J, Vantrappen G, et al. Erythromycin accelerates gastric emptying by inducing antral contractions and improved gastroduodenal coordination. Gastroenterology 1992;102:823–828.
Bologna SD, Hasler WL, Owyang C. Down-regulation of motilin receptors on rabbit colon myocytes by chronic oral erythromycin. J Pharmacol Exp Ther 1993;266:852–856.
Broad J, Mukherjee S, Samadi M, et al. Regional- and agonist-dependent facilitation of human neurogastrointestinal functions by motilin receptor agonists. Br J Pharmacol 2012;167:763–774.
Sanger GJ, Westaway SM, Barnes AA, et al. GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility. Neurogastroenterol Motil 2009;21:657–664, e30–e31.
Leming S, Broad J, Cozens SJ, et al. GSK962040: a small molecule motilin receptor agonist which increases gastrointestinal motility in conscious dogs. Neurogastroenterol Motil 2011;23:958–e410
Matsueda K, Hongo M, Tack J, et al. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut 2012;61:821–828.
Matsueda K, Hongo M, Tack J, et al. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia—100 mg t.i.d. is an optimal dosage. Neurogastroenterol Motil 2010;22:618–e173.
Tack J, Masclee A, Heading R, et al. A dose-ranging, placebo-controlled, pilot trial of Acotiamide in patients with functional dyspepsia. Neurogastroenterol Motil 2009;21:272–280.
Ejskjaer N, Vestergaard ET, Hellström PM, et al. Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Aliment Pharmacol Ther 2009;29:1179–1187.
Ejskjaer N, Dimcevski G, Wo J, et al. Safety and efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo-controlled study. Neurogastroenterol Motil 2010;22:1069–e281.
Wo JM, Ejskjaer N, Hellström PM, et al. Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting—randomized clinical study subset data. Aliment Pharmacol Ther 2011;33:679–688.
Ang D, Nicolai H, Vos R, et al. Influence of ghrelin on the gastric accommodation reflex and on meal-induced satiety in man. Neurogastroenterol Motil 2009;21:528–533.
Ejskjaer N, Wo JM, Esfandyari T, et al. A phase 2a, randomized, double-blind 28-day study of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil 2013;25:e140–e150.
McCallum RW, Lembo A, Esfandyari T, et al. Phase 2b, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil 2013;25:e705–e717.
Shin A, Camilleri M, Busciglio I, et al. Randomized, placebo-controlled, single-dose, crossover study of the effects of RM-131 in type 2 diabetics with documented delayed gastric emptying. Gastroenterology 2012;142:S839.
Lembo A, Camilleri M, McCallum RW, et al. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of RM-131 in patients with diabetic gastroparesis. Gastroenterology 2014;146:S158–S159.
Dukes GE, Barton M, Dewit O, et al. Safety/tolerability, pharmacokinetics (PK), and effect on gastric emptying (GE) with 14-days repeat oral dosing of the motilin receptor agonist, GSK962040, in healthy male and female volunteers. Neurogastroenterol Motil 2010;22:14–15.
Barshop K, Kuo B. The investigational drug camicinal for the treatment of gastroparesis. Expert Opin Investig Drugs 2014;24:1–8.
Walsh JH. Gastrointestinal hormones. In: Johnson LR, Barret KE, Gishan FK, et al., eds. Physiology of the gastrointestinal tract. 3rd ed. New York: Raven Press, 1994:1–128.
De Ponti F, Malagelada JR. Functional gut disorders: from motility to sensitivity disorders. A review of current and investigational drugs for their management. Pharmacol Ther 1998;80:49–88.
Scarpignato C, Pelosini I. Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility. Can J Gastroenterol 1999;13(Suppl. A):50A–65A.
Chan CL, Facer P, Davis JB, et al. Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency. Lancet 2003;361:385–391.
Bortolotti M, Coccia G, Grossi G, et al. The treatment of functional dyspepsia with red pepper. Aliment Pharmacol Ther 2002;16:1075–1082.
Frytak S, Moertel CG, O’Fallon JR, et al. Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann Intern Med 1979;91:825–830.
McCallum RW, Soykan I, Sridhar KR, et al. Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study. Aliment Pharmacol Ther 1999;13:77–80.
Chapman RW, Stanghellini V, Geraint M, et al. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol 2013;108:1508–1515.
Connell AM. The motility of the pelvic colon. II. Paradoxical motility in diarrhoea and constipation. Gut 1962;3:342–348.
Dinning PG, Wiklendt L, Maslen L, et al. Colonic motor abnormalities in slow transit constipation defined by high resolution, fibre-optic manometry. Neurogastroenterol Motil 2015 Jan 3. doi: 10.1111/nmo.12502. Epub 2015 Jan 3.
Kim DY, Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 2000;95:2698–2709.
Hoffman JM, Tyler K, MacEachern SJ, et al. Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivity. Gastroenterology 2012;142:844–854.
De Maeyer JH, Lefebvre RA, Schuurkes JA. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil 2008;20:99–112.
Camilleri M, Kerstens R, Rykx A, et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008;358:2344–2354.
Ke M, Zou D, Yuan Y, et al. Prucalopride in the treatment of chronic constipation in patients from the Asia-Pacific region: a randomized, double-blind, placebo-controlled study. Neurogastroenterol Motil 2012;24:999–e541.
Mendzelevski B, Ausma J, Chanter DO, et al. Assessment of the cardiac safety of prucalopride in healthy volunteers: a randomized, double-blind, placebo- and positive-controlled thorough QT study. Br J Clin Pharmacol 2012;73:203–209.
Camilleri M, Van Outryve MJ, Beyens G, et al. Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation—follow-up of patients from the pivotal studies. Aliment Pharmacol Ther 2010;32:1113–1123.
Camilleri M, Beyens G, Kerstens R, et al. Safety assessment of prucalopride in elderly patients with constipation: a double-blind, placebo-controlled study. Neurogastroenterol Motil 2009;21:1256–e117.
Quigley EM, Vandeplassche L, Kerstens R, et al. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronicconstipation—a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2009; 29:315–328.
Camilleri M, Kerstens R, Rykx A, et al. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 2008;358:2344–2354.
Coremans G, Kerstens R, De Pauw M, et al. Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial. Digestion 2003;67:82–89.
Müller-Lissner S, Rykx A, Kerstens R, et al. A double-blind, placebo-controlled study of prucalopride in elderly patients with chronic constipation. Neurogastroenterol Motil 2010;22:991–998, e255.
Goldberg M, Li YP, Johanson JF, et al. Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation—a 4-week, randomized, double-blind, placebo-controlled, dose-response study. Aliment Pharmacol Ther 2010;32:1102–1112.
Manini ML, Camilleri M, Goldberg M, et al. Effects of velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil 2010;22:42–49, e7–e8.
Camilleri M, Vazquez-Roque MI, Burton D, et al. Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil 2007;19:30–38.
Shin A, Acosta A, Camilleri M, et al. A randomized trial of 5-hydroxytryptamine 4-receptor agonist, YKP10811, on colonic transit and bowel function in functional constipation. Clin Gastroenterol Hepatol 2015;13:701–708, e1.
Gilet M, Eutamene H, Han H, et al. Influence of a new 5-HT4 receptor partial agonist, YKP10811, on visceral hypersensitivity in rats triggered by stress and inflammation. Neurogastroenterol Motil 2014;26:1761–1770.
Barrett KE, Keely SJ. Chloride secretion by the intestinal epithelium: molecular basis and regulatory aspects. Annu Rev Physiol 2000;62:535–572.
Camilleri M. Pharmacology of the new treatments for lower gastrointestinal motility disorders and irritable bowel syndrome. Clin Pharmacol Ther 2012;91:44–59.
Anggård E. The biological activities of three metabolites of prostaglandin E 1. Acta Physiol Scand 1966;66:509–510.
Cuppoletti J, Malinowska DH, Chakrabarti J, et al. Effects of lubiprostone on human uterine smooth muscle cells. Prostaglandins Other Lipid Mediat 2008;86:56–60.
Cuppoletti J, Chakrabarti J, Tewari KP, et al. Differentiation between human ClC-2 and CFTR Cl-. Am J Physiol Cell Physiol 2014;307:C479–C492.
Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther 2007;25:1351–1361.
Johanson JF, Morton D, Geenen J, et al. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastro